245 related articles for article (PubMed ID: 29931583)
41. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
42. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
Miura K; Takahashi H; Nakagawa M; Izu A; Sugitani M; Kurita D; Sakagami M; Ohtake S; Uchino Y; Hojo A; Kodaira H; Yagi M; Kobayashi Y; Iriyama N; Kobayashi S; Kiso S; Hirabayashi Y; Hatta Y; Takei M
Leuk Lymphoma; 2016; 57(6):1335-41. PubMed ID: 26390147
[TBL] [Abstract][Full Text] [Related]
44. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract][Full Text] [Related]
45. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
46. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
Kim H; Kim HJ; Kim SH
Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
[TBL] [Abstract][Full Text] [Related]
48. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
Dheur MS; Poirel HA; Ameye G; Tilman G; Saussoy P; Defour JP; Camboni A; Van Den Neste E; Coulie PG; van Baren N
Leuk Lymphoma; 2019 Apr; 60(4):1043-1052. PubMed ID: 30277098
[TBL] [Abstract][Full Text] [Related]
49. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
50. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
51. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
52. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells.
Kapp N; Stander XX; Stander BA
Anticancer Drugs; 2018 Jun; 29(5):429-439. PubMed ID: 29561307
[TBL] [Abstract][Full Text] [Related]
53. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
54. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
55. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
[TBL] [Abstract][Full Text] [Related]
56. A clinician's guide to double hit lymphomas.
Cheah CY; Oki Y; Westin JR; Turturro F
Br J Haematol; 2015 Mar; 168(6):784-95. PubMed ID: 25529575
[TBL] [Abstract][Full Text] [Related]
57. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
58. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Liu X; Wu H; Huang P; Zhang F
J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
[TBL] [Abstract][Full Text] [Related]
59. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
[TBL] [Abstract][Full Text] [Related]
60. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
